South Korean bioventure funding remained weak in the third quarter, with venture capital investment in the sector falling further from the previous three months, although a handful of companies managed to launch initial public offerings (IPOs) despite the sour market sentiment.
Venture capital investment in the area has continued to shrink this year, both in terms of the total amount and the proportion of funding from venture capital sources
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?